Pandemic News and Research

RSS

A pandemic is a global disease outbreak. During a pandemic, transmission can be anticipated in the workplace, not only from patient to workers in health care settings, but also among co-workers in general work settings. A pandemic would cause high levels of illness, death, social disruption, and economic loss. Everyday life would be disrupted because so many people in so many places become seriously ill at the same time. Impacts could range from school and business closings to the interruption of basic services such as public transportation and food delivery.

Vical reports net loss of $8.5 million for first-quarter 2010

Vical Incorporated today reported financial results for the quarter ended March 31, 2010. Revenues were $1.5 million for the first quarter of 2010 compared with $2.3 million for the first quarter of 2009, reflecting lower revenues under the company's license agreement with AnGes MG, Inc. Operating expenses were $10.1 million for the first quarter of 2010 compared with $10.6 million for the first quarter of 2009.

6 May 2010

Experts unveil roadmap to improve health and health delivery in the U.S.

A Commission of national health care experts convened by the Center for the Study of the Presidency and Congress has unveiled a roadmap and integrated approach that will put "health" back into our nation's health care system as well as address key opportunities following passage of health care reform legislation.

6 May 2010

Update on CEL-SCI's Phase III clinical trial of Multikine

CEL-SCI Corporation today provided an update on its planned Phase III clinical trial of its cancer immunotherapy drug candidate Multikine. The Company, together with its development partners Teva Pharmaceutical Industries and Orient Europharma, has already selected 40 of the planned 50 global medical centers where the Multikine Phase III study will be conducted.

6 May 2010

Vical commences enrollment in Phase 1 trial of Vaxfectin DNA pandemic influenza vaccine

Vical Incorporated today announced the enrollment of the first subject in its Phase 1 trial of the company's Vaxfectin®-formulated plasmid DNA (pDNA) pandemic influenza vaccine. The trial will be conducted in collaboration with the U.S. Naval Medical Research Center (NMRC).

5 May 2010

UK GTAC, MHRA approve Scancell's Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine

Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, today announced at BIO2010 in Chicago that its proposal to conduct a Phase I clinical trial on SCIB1, its DNA ImmunoBody® vaccine being developed for the treatment of melanoma, has been approved in the UK by the Gene Therapy Advisory Committee and by the Medicines and Healthcare products Regulatory Agency Medicines Division.

5 May 2010

Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it plans to initiate patient recruitment for a cancer immunotherapy study by year end. The pilot study seeks to demonstrate an improved immune function in cancer patients as a result of the Aethlon Hemopurifier removing tumor-secreted exosomes from the circulatory system.

4 May 2010

MicroStockProfit.com releases investment report on Vical

MicroStockProfit.com announces an investment report featuring Vical Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

4 May 2010

Author of new study calls for responsible media coverage of public health emergencies

A study of emergency department activity before and during the H1N1 influenza pandemic highlights the role public fear can play in unnecessarily straining medical facilities and will aid in ongoing preparations for public health emergencies, according to the authors.

4 May 2010

H1N1 positivity highest among children

More than 99 percent of specimens tested for influenza were positive for H1N1 over approximately the past 11 months, according to a report released today from Quest Diagnostics Incorporated ( DGX). The Quest Diagnostics Health Trends™ Report suggests that H1N1 "crowded out" other influenza viruses to be the dominant flu virus of the 2009-2010 flu season.

4 May 2010

Older children hospitalized with pandemic H1N1 influenza in 2009: Study

Children hospitalized with pandemic H1N1 influenza in 2009 were older and more likely to have underlying medical conditions than children hospitalized with seasonal influenza during prior flu seasons, according to a study to be presented Tuesday, May 4 at the Pediatric Academic Societies annual meeting in Vancouver, British Columbia, Canada.

4 May 2010

NIAID researchers initiate trial of DAS181 in patients with asthma, bronchiectasis

NexBio, Inc. announced today the initiation of a trial of DAS181 (Fludase®) in patients with the respiratory conditions asthma and bronchiectasis, being conducted by researchers with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This trial will examine the effects of DAS181 in subjects with well-controlled or stable pulmonary disease.

3 May 2010

Researcher finds evidence of how human behavior can influence emergence of infectious disease

After studying the interactions of human and animal populations in Africa, Kathleen Alexander, associate professor of wildlife science in Virginia Tech's College of Natural Resources, found powerful evidence of how human behavior can influence the emergence of infectious disease in humans and animals.

3 May 2010

Seasonal flu vaccine ups the risk of getting H1N1 flu

Initial reports linking seasonal flu vaccine and getting swine flu or H1N1 flu emerged September 2009 in Canada. In spring 2009 many people who acquired pandemic H1N1 flu had been initially vaccinated with seasonal flu vaccine. This triggered four additional studies in Canada to explore the link further. The studies included 2,700 patients with or without H1N1. The first of the studies showed a surprising 68 percent rise of risk of development of H1N1 flu in those vaccinated with seasonal flu shot. The other 3 studies showed increase of risk of H1N1 flu by 1.4 to 1.5 times with the original flu shot.

2 May 2010

CDC report shows increase in seasonal flu vaccinations, greatest increase among children

More Americans were vaccinated against seasonal flu during the 2009-10 season (40 percent of eligible population) than during the previous flu season (33 percent of eligible population), according to a report by the Centers for Disease Control and Prevention.

30 Apr 2010

Genworth Financial reports first-quarter 2010 net income of $212M against loss last year

Genworth Financial, Inc. today reported results for the first quarter of 2010. Net income, before provision for noncontrolling interests, was $212 million, or $0.43 per diluted share, compared with a net loss of $469 million, or $1.08 per diluted share, in the first quarter of 2009.

30 Apr 2010

CDC presents clinical trial results of Biojector 2000 at 13th Annual Conference on Vaccine Research

Bioject Medical Technologies Inc., a leading developer of needle-free injection therapy systems (NFITS), today announced that the Centers for Disease Control and Prevention (CDC) and its collaborating institutions presented the latest results of its clinical trial of the Biojector® 2000 at the 13th Annual Conference on Vaccine Research, sponsored by the National Foundation for Infectious Diseases and held in Bethesda, Maryland April 26 - 28, 2010.

30 Apr 2010

Practicing NPIs may help limit transmission of pandemic flu: Study

Practicing non-pharmaceutical interventions such as hand-washing and mouth covering may help limit the transmission of the pandemic flu, but more research on these measures is critical according to a new study appearing in the May issue of AJIC: American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology, Inc.

30 Apr 2010

Newsweek examines advocates' views of PEPFAR under Obama

Newsweek examines HIV/AIDS advocates' concerns that the Obama administration's focus on the six-year, $63 billion Global Health Initiative (GHI) is compromising PEPFAR's reach.

30 Apr 2010

BD second-quarter revenues up 7.0% to $1.845 billion

BD (Becton, Dickinson and Company) today reported quarterly revenues of $1.845 billion for the second fiscal quarter ended March 31, 2010, representing an increase of 7.0 percent from the prior-year period, or 6.6 percent on a foreign currency-neutral basis.

From BD (Becton, Dickinson and Company) 29 Apr 2010

Preventing HPV infection could slow HIV epidemic, say researchers

Men infected with human papillomavirus are at greater risk of becoming infected with human immunodeficiency virus than men who are not HPV positive, according to researchers at the University of North Carolina at Chapel Hill.

29 Apr 2010

Pandemic News and Research

Further Reading

Vical reports net loss of $8.5 million for first-quarter 2010

Experts unveil roadmap to improve health and health delivery in the U.S.

Update on CEL-SCI's Phase III clinical trial of Multikine

Vical commences enrollment in Phase 1 trial of Vaxfectin DNA pandemic influenza vaccine

UK GTAC, MHRA approve Scancell's Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine

Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study

MicroStockProfit.com releases investment report on Vical

Author of new study calls for responsible media coverage of public health emergencies

H1N1 positivity highest among children

Older children hospitalized with pandemic H1N1 influenza in 2009: Study

NIAID researchers initiate trial of DAS181 in patients with asthma, bronchiectasis

Researcher finds evidence of how human behavior can influence emergence of infectious disease

Seasonal flu vaccine ups the risk of getting H1N1 flu

CDC report shows increase in seasonal flu vaccinations, greatest increase among children

Genworth Financial reports first-quarter 2010 net income of $212M against loss last year

CDC presents clinical trial results of Biojector 2000 at 13th Annual Conference on Vaccine Research

Practicing NPIs may help limit transmission of pandemic flu: Study

Newsweek examines advocates' views of PEPFAR under Obama

BD second-quarter revenues up 7.0% to $1.845 billion

Preventing HPV infection could slow HIV epidemic, say researchers

Best practices - optimize qPCR processes for pathogen detection eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News